Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Phio Pharmaceuticals Corp. (PHIOW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.0400+0.0118 (+41.84%)
At close: 01:38PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0282
Open0.1316
Bid0.1120 x 1100
Ask0.1420 x 1400
Day's Range0.0280 - 0.0448
52 Week Range0.0280 - 0.0448
Volume33,347
Avg. VolumeN/A
Market Cap726,576
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-1.1290
Earnings DateNov 10, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for PHIOW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting

      Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new study data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. The data from this study in an in vivo hepatocarcinoma model shows that PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response.

    • PR Newswire

      Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

      Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.

    • PR Newswire

      Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

      Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.

    Advertisement
    Advertisement